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Abstract
AIM: To determine if diabetes mellitus (DM) is as-
sociated with increased risk of colorectal adenomas in 
younger subjects.
METHODS: This was a retrospective cohort study of 
375 patients undergoing index colonoscopy at a single 
tertiary care center in the United States. Three cohorts 
of patients matched for exam date and gender were 
compared: (1) ages 40-49 years with DM; (2) ages 
40-49 years without DM; and (3) ages 50-59 years 
without DM. Data collected included demographics, 
co-morbidities, colonoscopy and pathology results. 
Adenoma detection rates (ADR) were calculated and 
compared. Conditional logistic regression analysis was 
performed to determine the association between each 
cohort and ADR. 
RESULTS: One hundred and twenty-five patients ages 
40-49 with DM met study eligibility criteria. Patients in 
the other two cohorts were randomly selected, match-
ing for date of exam and gender. ADR was 14.4% in 
those ages 40-49 years without DM, 30.4% in those 
ages 40-49 years with DM, and 32.0% in those ages 
50-59 years without DM. Compared to those ages 
40-49 years without DM, ADR was higher in those ages 
40-49 years with DM (OR = 3.1; 95%CI: 1.5-6.4; P  = 
0.002) and those ages 50-59 years without DM (OR = 
2.9; 95%CI: 1.5-5.6; P  = 0.002). There was no differ-
ence between the ADR in those ages 40-49 years with 
DM and those ages 50-59 years without DM (P  = 0.83). 
CONCLUSION: DM was associated with higher risk 
of colorectal adenomas in patients ages 40-49 years. 
These subjects harbored as many adenomas as those 
at the standard screening age of 50-59 years without 
DM. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Diabetes mellitus (DM) is associated with in-
creased risk of colorectal neoplasia. It is unknown if pa-
tients with DM should be screened more aggressively. 
Three cohorts were compared: patients aged 40-49 
years with DM, 40-49 years without DM, and 50-59 
years without DM. DM was associated with increased 
risk for developing colorectal adenomas in patients 
40-49 years old. This is the first study to specifically ex-
amine these differences among patients with or without 
DM younger than the recommended colorectal cancer 
screening age of 50 years. 
Vu HT, Ufere N, Yan Y, Wang JS, Early DS, Elwing JE. Diabetes 
mellitus increases risk for colorectal adenomas in younger pa-
tients. World J Gastroenterol 2014; 20(22): 6946-6952  Available 
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INTRODUCTION
Colorectal cancer (CRC) is the third most common can-
cer affecting both men and women and second most 
common cause of  cancer death in the United States. In 
2011, there were an estimated 141000 new diagnoses of  
CRC and 49000 deaths associated with CRC[1]. There 
has been a decline in the incidence of  CRC over the past 
two decades, which has been attributed to screening by 
colonoscopy, and removal of  pre-malignant colon polyps. 
The United States Preventive Services Task Force. Multi-
Society Task Force, and American College of  Gastroen-
terology guidelines recommend initiating CRC screening 
at 50 years of  age for those at average risk, and earlier 
for those at increased risk, such as those with family 
history[2-4]. The American College of  Gastroenterology 
guidelines also recommend earlier screening in African-
Americans and awareness of  increased risk of  CRC in 
patients with obesity and history of  smoking[4].
Diabetes mellitus type 2 (DM) has been found to be 
associated with a 20%-60% increased risk of  CRC[5,6]. 
It is postulated that insulin resistance and the resulting 
hyperinsulinemia may promote carcinogenesis directly 
by stimulating colonic cell growth[7,8]. In addition, insulin 
is thought to act indirectly by up-regulating growth hor-
mone receptors in the liver to increase levels of  insulin-
like growth factor (IGF)-1 and inhibiting IGF binding 
proteins which also results in elevated levels of  free 
IGF-1[7,8]. IGF-1 is theorized to then enhance cell pro-
liferation and inhibit apoptosis, thus promoting tumor 
growth. Insulin and IGF-1 may also act through Ras acti-
vation which leads to increased sensitivity to growth fac-
tors in colonic cells and possible accelerated progression 
from adenoma to carcinoma[7,8]. Observational studies 
have shown an increased CRC risk with hyperinsulinemia 
as well as with elevated IGF-1 levels[9]. In addition, there 
have been data showing a similar association with adeno-
matous polyps, the precursor to CRC[10-13]. 
There currently are no modifications in CRC screen-
ing guidelines for people with DM. In particular, it is 
unknown if  patients with DM should be screened ear-
lier than patients at average risk for CRC. The aim of  
this study was to determine if  DM is associated with 
increased risk of  developing colorectal adenomas in sub-
jects ages 40-49 years compared to an age matched group 
without DM and to average risk non-diabetics at the stan-
dard screening age of  50 years or older. Our hypothesis 
was that patients with DM would have increased rates of  
adenomas compared to those without DM.
MATERIALS AND METHODS
The study was approved by the Washington University 
Institutional Review Board and Siteman Cancer Center 
Protocol Review and Monitoring Committee. We per-
formed a retrospective cohort study of  patients undergo-
ing colonoscopy at a single center over a six-year period, 
comparing three cohorts matched for date of  exam and 
gender: (1) ages 40-49 years without DM; (2) ages 40-49 
years with DM; and (3) ages 50-59 years without DM. 
Subjects were identified from an endoscopy database 
among patients undergoing index colonoscopies at Wash-
ington University in St. Louis, Missouri between June 1, 
2005 and June 30, 2011. Medical records were reviewed 
to determine DM status. All patients ages 40-49 years 
with DM undergoing index colonoscopies within the 
study period were first identified. Patients in the other 
two cohorts were then randomly selected in a 1:1 ratio, 
matching for date of  exam and gender. Inclusion crite-
ria also included index (first) colonoscopy, colonoscopy 
completed to the cecum, and excellent or good bowel 
preparation. Exclusion criteria included incomplete 
colonoscopy, poor or fair bowel preparation, history of  
prior colonoscopy, inflammatory bowel disease, polyposis 
syndrome, prior colectomy, personal history of  CRC, or 
family history of  CRC in a first-degree relative. 
Medical records were reviewed to obtain data on de-
mographics including age, gender, ethnicity, and height 
and weight to determine body mass index (BMI). Pres-
ence or absence of  DM was determined by medical his-
tory obtained by nurses at the time of  colonoscopy and 
corroborated by review of  medical records and medica-
tion lists. DM status was also reviewed in terms of  type 
of  diabetic medication used and hemoglobin A1C level 
(HgbA1C) as a marker of  glycemic control. Co-morbid-
ities including presence of  hypertension, hyperlipidemia, 
tobacco use, and alcohol use were also recorded. Fam-
ily history of  CRC was determined by medical history 
obtained by nurses and interview by colonoscopist at 
the time of  colonoscopy and corroborated by review 
of  medical records. Colonoscopy and pathology reports 
were reviewed to obtain data on indication, bowel prepa-
ration quality, completeness of  procedure to cecum, and 
polyp characteristics (number, location, size, and pathol-
ogy). Histopathologic diagnoses were recorded; high risk 
state was defined as adenoma size ≥ 1 cm, number of  
adenomas ≥ 3, villous features, or high grade dysplasia. 
If  multiple polyps were placed in the same specimen con-
tainer, then pathology reports were closely reviewed to 
ascertain correct histopathologic diagnosis of  each polyp. 
Polyp and adenoma detection rates (ADR), defined as 
the proportion of  screened subjects in whom at least one 
polyp or adenoma was identified respectively, were calcu-
lated for each cohort.
Statistical analysis
Statistical analyses include comparisons of  patient de-
mographics and clinical characteristics among the three 
cohorts and use regression models to determine associa-
tion of  group status with ADR, adjusting for patient de-
mographics and clinical characteristics. ANOVA was used 
to compare continuous variables (age, body mass index) 
among the three cohorts, and χ 2 test or Fisher exact test 
was used to compare categorical variables (gender, ethnic-
ity, hypertension, hyperlipidemia, indication) among the 
three groups. For regression analyses, conditional logistic 
regression model was used since the patients in different 
cohorts were matched by date of  exam and gender. Con-
Vu HT et al . Colorectal adenomas in younger patients
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ditional logistic regression analysis was performed to de-
termine the association between each cohort and ADR. 
Variables included in the conditional logistic regression 
model for adjustment were ethnicity, BMI, tobacco, and 
alcohol. Sensitivity analyses after further allowances for 
hypertension and hyperlipidemia were also performed. 
Data analyses were performed by using SAS software 
version 9.2 (Cary, North Carolina, United States).
RESULTS
A total of  3749 patients between the ages of  40-49 years 
underwent index colonoscopy between June 2005 and 
June 2011. After manual review of  medical records, we 
found that 193 patients ages 40-49 years had DM at the 
time of  their colonoscopy, but 68 of  these patients were 
excluded due to poor or fair bowel preparation. There-
fore, 125 patients ages 40-49 years with DM met study 
eligibility criteria and were included in the study. We then 
randomly selected 125 patients ages 40-49 years with-
out DM and 125 patients ages 50-59 years without DM, 
matching for date of  exam and gender. 
Baseline characteristics
Baseline characteristics of  the three cohorts are found 
in Table 1. Mean age was 46 years in the two younger 
cohorts and 54 years in the older cohort. Gender was 
matched for in all three cohorts with 63.2% female. 
There was no difference in ethnicity among the three 
cohorts with 35.2% African-Americans in the younger 
cohort without DM, 46.0% with DM, and 39.2% in the 
older cohort. There were significantly greater rates of  co-
morbid obesity (higher mean BMI), hypertension, and hy-
perlipidemia in the cohort with DM as expected. Among 
patients with DM, 77.7% were on oral hyperglycemic 
medications, 52.3% were on insulin, and mean HgbA1C 
was 7.4%.
Indication for colonoscopy was screening in 83% of  
the patients ages 50-59 years without DM and 15% in the 
younger cohorts. Nearly all of  the screening colonosco-
pies in the younger cohorts were performed in patients 
in their late forties close to the recommended age of  50 
years to start CRC screening. All other colonoscopies 
were performed for diagnostic purposes including gastro-
intestinal bleeding, change in bowel habits, or abdominal 
pain. 
Polyp and adenoma detection rates
The polyp and adenoma detection rates are found in 
Table 2. The ADRs were 14.4% in those ages 40-49 years 
without DM (17.4% in men, 12.7% in women), 30.4% in 
those ages 40-49 years with DM (39.1% in men, 25.3% 
in women), and 32.0% in those ages 50-59 years without 
DM (41.3% in men, 26.6% in women). Compared to 
those ages 40-49 years without DM, there was a statisti-
cally significant higher association between cohort and 
presence of  adenoma in those ages 40-49 years with DM 
(adjusted OR = 2.6, 95%CI: 1.4-4.9; adjusted OR=3.1, 
95%CI: 1.5-6.4; P = 0.002) and those ages 50-59 years 
without DM (adjusted OR = 2.8, 95%CI: 1.5-5.2; ad-
justed OR = 2.9, 95%CI: 1.5-5.6; P = 0.002) in both uni-
variate and multivariate analyses. A slightly stronger asso-
ciation was found in men (adjusted OR = 4.7 in patients 
ages 40-49 years with DM, adjusted OR = 4.0 in those 
ages 50-59 years without DM) than in women (adjusted 
OR = 2.5 in patients ages 40-49 years with DM, adjusted 
OR = 3.3 in those ages 50-59 years without DM). De-
spite differences in terms of  prevalence of  hypertension 
and hyperlipidemia between the two younger cohorts, 
sensitivity analyses after further allowances for the two 
co-morbidities showed a similar significant association 
(OR = 3.2, 95%CI: 1.5-7.1) for patients ages 40-49 years 
with DM and (OR = 3.0; 95%CI: 1.5-5.9) for those ages 
50-59 without DM. There was no statistically significant 
difference between cohort and presence of  adenoma in 
those ages 40-49 years with DM and those ages 50-59 
years without DM (P = 0.78 on univariate analysis and P 
= 0.83 on multivariate analysis). 
High risk state
The prevalence of  high risk state, defined as adenoma 
size ≥ 1 cm, presence of  high grade dysplasia or villous 
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Table 1  Baseline characteristics
40-49 yr without DM (n  = 125) 40-49 yr with DM (n  = 125) 50-59 yr without DM (n  = 125) P -value
Age (yr, mean ± SD) 45.7 ± 3.1 46.1 ± 2.7 53.7 ± 2.7 < 0.001
Gender (% Female) 63.2 63.2 63.2 1.0
Ethnicity (% African-American) 35.2 46.0 39.2   0.13
Body mass index 
(kg/m2, mean ± SD)
29.6 ± 7.4 36.0 ± 9.6 28.6 ± 7.0 < 0.001
Hypertension (%) 40.8 76.6 46.8 < 0.001
Hyperlipidemia (%) 16.9 50.0 25.0 < 0.001
Indication (%)
   Screening 15.3 14.8 83.2 < 0.001
   Gastrointestinal bleeding 41.9 45.9   7.2 < 0.001
   Change in bowel habits 29.8 30.3   5.6 < 0.001
   Abdominal pain   6.5   3.3   1.6  0.13
   Other   2.4   3.3   1.6  0.69
DM: Diabetes mellitus. 
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these cohorts having significantly more adenomas than 
those ages 40-49 years without DM. To our knowledge, 
this is the first study to specifically examine these differ-
ences among patients with or without DM younger than 
the recommended CRC screening age of  50 years.
In a large population-based retrospective cohort study, 
Limburg et al[14] showed an association between DM and 
increased CRC risk with a standardized incidence ratio of  
1.39. Hu et al[15] also demonstrated a similar association 
in the Nurses’ Health Study. After 18 years of  follow-up, 
relative risk for CRC was 1.43 in those with documented 
DM at baseline. A recent meta-analysis by Yuhara et al[6] 
found that DM was an independent risk factor for CRC 
and was associated with an increased risk for CRC in 
both men and women even after controlling for smoking, 
obesity, and physical exercise with relative risk of  1.37. 
Prior studies have also shown higher prevalence of  
adenomas, the precursor to CRC, in patients with DM 
compared to those without DM. In a prospective study, 
Schoen et al[10] found an association between increased 
levels of  insulin and IGF-1 and presence of  colorectal 
adenomas as well as advanced adenomas in 458 asymp-
tomatic patients who underwent flexible sigmoidoscopy. 
Elwing et al[11] previously compared 100 women with DM 
to 500 controls without DM undergoing index colonos-
copy and found that women with DM had higher rates 
of  adenomas (37% vs 24%, OR = 1.82) and advanced 
adenomas (14% vs 6%, OR = 2.38). With multivariate 
analysis, they found that DM was an independent predic-
tor for the presence of  both adenomas and advanced 
adenomas. Eddi et al[12] performed a retrospective case-
control study of  patients with or without adenomas and 
found that DM, insulin exposure, and thiazolidinedione 
use was associated with developing adenomas. More re-
cently, Kanadiya et al[13] performed a retrospective cross-
sectional analysis of  405 patients with DM and 3038 
without DM undergoing first colonoscopy. DM was as-
sociated with increased risk of  adenoma (OR = 1.35) and 
ADR was higher in diabetics (29.3% vs 23.9%). However, 
none of  these studies compared ADR in patients with or 
without DM in patients under the age of  50 years.
There is consensus among guidelines that CRC 
screening should be initiated in average-risk individu-
als starting at 50 years of  age[2-4]. The rationale for this 
threshold is that the risk of  CRC and advanced adenomas 
is low in younger individuals. The reported incidence of  
features, or number of  adenomas ≥ 3 in the three co-
horts are found in Table 3. Prevalence of  high risk state 
were 7.2% in those ages 40-49 years without DM (10.9% 
in men, 5.1% in women), 9.6% in those ages 40-49 with 
DM (10.9% in men, 8.9% in women), and 12.8% in those 
ages 50-59 years without DM (15.2% in men, 11.4% in 
women). Compared to those ages 40-49 years without 
DM, we found trends towards higher prevalence of  high 
risk state in those ages 40-49 years with DM and those 
ages 50-59 years without DM, but these were not statisti-
cally significant. There was no statistically significant dif-
ference between the prevalence of  high risk state in those 
ages 40-49 years with DM and those ages 50-59 years 
without DM (P = 0.4). 
Polyp characteristics
Among patients with adenomas, mean number of  adeno-
mas per patient, location of  adenomas, and prevalence 
of  advanced adenomas were not statistically significant 
among the three cohorts (Table 4). There were one, zero, 
and two synchronous CRC found in the cohorts ages 
40-49 years without DM, ages 40-49 years with DM, and 
ages 50-59 years without DM, respectively.
DISCUSSION
In this retrospective cohort study, DM was associated 
with a significantly higher risk of  developing colorectal 
adenomas in patients ages 40-49 years. These subjects 
harbored as many adenomas as those at the standard 
screening age of  50-59 years without DM, with both of  
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Table 2  Polyp and adenoma detection rates
40-49 yr 
without DM 
(n  = 125)
40-49 yr 
with DM 
(n  = 125)
50-59 yr 
without DM 
(n  = 125)
Polyp detection rate (%) 31.2 49.6 50.4
Adenoma detection rate (%) 14.4 30.4 32.0
   Univariate OR (95%CI) 1.0 (reference) 2.6 (1.4-4.9) 2.8 (1.5-5.2)
   Multivariate OR (95%CI)1 1.0 (reference) 3.1 (1.5-6.4) 2.9 (1.5-5.6)
1Analyses were adjusted for ethnicity, body mass index, smoking, and 
alcohol use; DM: Diabetes mellitus. 
Table 3  Prevalence of high risk state
40-49 yr 
without DM
(n  = 125)
40-49 yr 
with DM
(n  = 125)
50-59 yr 
without DM
(n  = 125)
Prevalence of high risk state1 
(%)
7.2 9.6 12.8
Univariate OR (95%CI) 1.0 (reference) 1.4 (0.6-3.4) 1.9 (0.8-4.5)
P = 0.5 P = 0.1
1High risk state was defined as adenoma number ≥ 3, size ≥ 1 cm, high 
grade dysplasia, or villous features; DM: Diabetes mellitus.
Table 4  Polyp characteristics among patients with adenomas 
(n  = 96)
40-49 yr 
without DM 
(n  = 18)
40-49 yr 
with DM 
(n  = 38)
50-59 yr 
without DM 
(n  = 40)
P -value
Number of adenomas 
(mean)
1.5 1.7 1.5 0.69
Location (% proximal) 38.9 55.3 52.5 0.50
Advanced adenoma (%) 50.0 31.6 40.0 0.40
   Size ≥ 1 cm (%) 33.3 18.4 32.5 0.30
   Villous features (%) 27.8 13.2 15.0 0.36
   High grade dysplasia 
   (%)
0   2.6 2.5 0.79
DM: Diabetes mellitus. 
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CRC per 100000 population rises from 45.9 at age 40-49 
years, to 133.3 at age 50-59 years and 268.2 at age 60-69 
years[16]. In two screening colonoscopy studies performed 
in asymptomatic patients ages 40-49, the prevalence 
of  advanced adenomas was found to be 2% and 3.5% 
with no cases of  CRC[17,18]. The evidence from our study 
shows that the existence of  DM in patients ages 40-49 
years increases their risk of  adenomas and advanced ad-
enomas to that of  patients ages 50-59 years without DM. 
Greater DM severity as determined by the need for 
insulin therapy and HgbA1C levels, a measure of  DM 
control, has also been found to be associated with in-
creased risk for both CRC as well as adenomas. In a pro-
spective population study, Khaw et al[19] reported a three-
fold risk for CRC in known diabetics. In addition, they 
found that there was a 1.34 increase in relative risk with 
every 1% increase in HgbA1C concentrations. Yang et 
al[20] demonstrated a two-fold increased risk of  CRC in 
patients with DM on insulin therapy for greater than one 
year compared to non-insulin using patients with DM. 
Chung et al[21] found that diabetic patients with adenomas 
showed significantly higher rates of  chronic insulin ther-
apy compared to age and sex-matched controls, and that 
chronic insulin therapy was associated with three times 
the risk of  having colorectal adenomas among a cohort 
of  325 patients with DM who underwent colonoscopy. 
Siddiqui et al[22] found that poorly controlled diabetics 
with HgbA1C ≥ 7.5% had greater number of  adenomas, 
more advanced lesions, greater use of  exogenous insulin, 
and younger age of  presentation in a retrospective co-
hort study of  652 male veterans with DM and adenomas. 
In our cohort with DM, 52% were on chronic insulin 
therapy and mean HgbA1C was 7.4, implying that at least 
half  of  our patients with DM qualified as having severe 
disease and were at higher risk for adenomas despite their 
relatively young age. 
Our study had several limitations. It was a retrospec-
tive cohort study with inherent limitations in this design 
study. To date, there have been no reported prospective 
studies evaluating the development of  adenomatous 
polyps in patients with DM or specifically those younger 
than the age of  50 years. There was also a relatively low 
sample size in each of  the cohorts, likely due to low rates 
of  diabetes in patients 40-49 years old. Another limitation 
of  our study is that it was not performed in an average 
risk screening population. However, patients under the 
age of  50 years are currently not recommended to under-
go screening colonoscopy unless they are at increased risk 
for CRC. The only way to establish risk in this younger 
population would be to design a prospective study of  
asymptomatic, average-risk young patients with and with-
out DM to compare risk of  adenomas and CRC. Prior 
published studies have also encountered this limitation. 
In a recent study by Gupta et al[23] asymptomatic patients 
aged 40-49 years undergoing screening for a family his-
tory of  polyps were compared to a control population of  
40-49 years olds with symptoms. In addition, longitudinal 
studies following patients with DM over time would be 
needed to study more clinically significant outcomes such 
as incidence of  CRC and related mortality to address 
whether the increase in number of  adenomas found in 
patients with DM leads to higher rates of  CRC and relat-
ed mortality. Such a study would require at least ten years 
of  follow-up to answer these questions. In the meantime, 
retrospective cohort studies such as ours are the only 
means to examine a younger population of  diabetics. 
The same may be said for studies evaluating the increased 
CRC risk for African Americans, in which no prospective 
studies have been performed. However, those retrospec-
tive studies have accumulated enough evidence to change 
the American College of  Gastroenterology guidelines 
to recommend initiating CRC screening earlier at age 45 
years[4,24].
Our study controlled for age, gender, and date of  
procedure by design. Males have been established to 
have higher risk for CRC and adenomas[1,25]. Dates of  
procedures were controlled to take into account differ-
ent endoscopists and to decrease accrual bias. Although 
we adjusted our analyses by ethnicity, tobacco, alcohol, 
and BMI, our study did not control for additional pos-
sible confounding risk factors such as diet and exercise. 
There were higher rates of  African-Americans in the DM 
cohort, but this did not reach statistical significance and 
ethnicity was adjusted for in the multivariate analysis. A 
prior study by He et al[26] demonstrated increased risk of  
CRC associated with DM (RR 1.19), which was consis-
tent across four ethnic populations including Caucasians, 
African-Americans, Japanese-Americans, and Latinos in a 
prospective analysis of  the population-based Multiethnic 
Cohort. The other variables that were significantly dif-
ferent among our three cohorts are to be expected: age 
(which was a defining feature of  the cohorts) as well as 
co-morbidities known to be associated with DM (obesity, 
hypertension, and hyperlipidemia). However, the ADR 
differences in the three cohorts still remained significant 
after multivariate analysis adjusted for the presence of  
ethnicity, BMI, smoking, and alcohol use. 
In our study, we noted that the bowel preparation was 
poor or fair in one-third of  patients with DM, causing 
their exclusion from the cohort. Diabetic patients may 
have inadequate bowel preparation due to autonomic 
neuropathy and gastrointestinal dysmotility associated 
with their DM. This may lead to decreased detection of  
both adenomas and CRC in patients with DM, since bowel 
preparation is vital to high-quality screening colonoscopy. 
If  pre-malignant polyps are less frequently detected and 
removed in diabetic patients due to inadequate visibility, 
this may lead to the development of  more interval CRC 
in these patients. In addition, decreased detection of  both 
adenomas and CRC may lead to the underestimation of  
their risk in those with DM. At our institution, we are 
recommending that patients with DM undergo a more 
stringent bowel preparation to ensure adequate visibility 
and effective screening.
Our data may have important public health implica-
tions given the estimated 25.8 million people affected by 
DM with rapidly rising incidence in the United States[27]. 
Other studies have suggested that DM increases the risk 
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for development of  CRC and adenomatous polyps, the 
pre-malignant precursor to CRC. Our study confirms 
this increased risk in patients with DM who were up to 
a decade younger than the recommended screening age 
of  50 years. These findings need to be validated in fur-
ther studies, optimally with prospective and longitudinal 
studies in younger diabetics that are asymptomatic and at 
average risk for CRC. If  our results are corroborated, this 




Type 2 diabetes mellitus (DM), a state of hyperinsulinemia, is associated with 
increased risk of colorectal neoplasia including colorectal cancer (CRC) and its 
precursor colonic adenomas. It is unknown if patients with DM require more ag-
gressive screening than patients at average risk for CRC. 
Research frontiers
Patients with adenomas found on colonoscopy are at increased risk for devel-
oping CRC. DM is associated with increased rates of developing adenomas. 
The research hotspot is determining if patients with DM develop adenomas at 
an age earlier than the standard recommended screening age of 50 years old.
Innovations and breakthroughs
Prior studies including population and prospective cohort studies have found 
that DM is associated with a 20%-60% increased risk of CRC. In addition, there 
have been data showing a similar association with adenomatous polyps, the 
precursor to CRC. There is also data that this risk is elevated with greater DM 
severity as evidenced by insulin requirement and HgbA1C. However, none of 
these studies evaluated patients with or without DM under the age of 50 years.
Applications
DM was associated with increased risk for developing colorectal adenomas in 
patients 40-49 years old. This is the first study to specifically examine these 
differences among patients with or without DM younger than the recommended 
colorectal cancer screening age of 50 years.
Terminology
Polyp and adenoma detection rates are defined as the proportion of screened 
subjects in whom at least one polyp or adenoma was identified respectively. 
High risk state was defined as adenoma size ≥ 1 cm, number of adenomas ≥ 
3, villous features, or high grade dysplasia.
Peer review
This is a well-written manuscript on the frequency of adenoma detection in 
subjects with and without diabetes mellitus. The issue is relevant and data are 
original. The study is adequately designed with clear results.
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